Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)
Mandate

Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)

November 03, 2014

Vinge has advised HealthCap VI L.P in connection with the execution of an investment agreement with Cortendo AB (publ) (“Cortendo”). The investment will be effected through a directed new issue of shares to HealthCap and other investors.

The new issue must be approved by a shareholders’ meeting of Cortendo and the meeting is expected to be held on or about 1 December 2014.Cortendo is a Swedish biopharmaceutical company which has its base in the United States.

Vinge’s team consisted of responsible partner Johan Winnerblad and associate Alex Miler.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026